Amgen (AMGN) experienced a fervor of financial activity with several financial institutions and management groups both buying and selling its shares. Investment firms such as Jump Financial, FORA Capital, Alliancebernstein, and Adage Capital Partners decreased their stakes, while Ameriflex Group, Hancock Whitney Corp, and EP Wealth Advisors substantially increased their positions. Share price changes were informed by Leerink Partners, UBS, and Piper Sandler maintaining neutral to positive ratings and periodically raising their price target. Amgen expanded its innovative capabilities by investing over $600 million in a new R&D hub in California. It has announced full results from part 1 of the Phase 2 study of MariTide, the experimental obesity drug. Despite perceived setbacks with their gastric cancer drug and competition from Novo Nordisk, the company shows potential with its dividend power, earnings, and overall value for long-term investment.
Amgen AMGN News Analytics from Mon, 24 Feb 2025 08:00:00 GMT to Sat, 06 Sep 2025 23:21:59 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -4
